📊 LGVN Key Takeaways
Is Longeveron Inc. (LGVN) a Good Investment?
Longeveron is a pharmaceutical company in acute financial distress with collapsing revenue (-49.9% YoY), unsustainable operating losses of -$23.3M on only $1.2M revenue, and negative free cash flow of -$18.9M. With approximately $4.7M in cash and monthly burn rates implying ~3 months of runway, the company faces imminent liquidity crisis without significant capital infusion or dramatic burn reduction.
Longeveron exhibits minimal revenue with a high gross margin but suffers from extremely negative operating and net margins, reflecting a pre-commercial, cash-consuming profile. With only $4.66M in cash versus roughly $18.6M in annual operating outflows and a modest 1.33x current ratio, liquidity is thin and raises near-term dilution or going-concern risk. Low leverage is a positive, but the 49.9% YoY revenue decline and persistent losses overshadow strengths.
Why Buy Longeveron Inc. Stock? LGVN Key Strengths
- Gross margin of 67% demonstrates acceptable unit economics if revenue scale could be achieved
- Minimal debt burden with Debt/Equity of 0.03x reduces financial leverage risk
- Diluted EPS improved 50.8% YoY indicating partial stabilization of losses from prior year
- Low financial leverage (Debt/Equity 0.03x)
- High gross margin on limited revenue (67%)
- Low capex requirements supporting flexible spending (CapEx $245K)
LGVN Stock Risks: Longeveron Inc. Investment Risks
- Critical cash runway of approximately 3 months based on $4.7M cash against $18.6M annual operating burn rate
- Revenue collapse of 49.9% YoY signals severe loss of commercial traction or clinical setbacks
- Operating margin of -1942.2% and net margin of -1893.6% are completely unsustainable and indicate fundamental business model failure at current scale
- Negative free cash flow of -$18.9M with no path to positive cash generation visible in near term
- Pharmaceutical sector capital intensity requires sustained funding access that appears increasingly constrained
- Severe cash burn with limited cash balance implying near-term financing/dilution risk
- Extremely negative profitability (Operating margin -1942%, Net margin -1894%)
- Revenue contraction (-49.9% YoY) increases going-concern risk and execution uncertainty
Key Metrics to Watch
- Monthly operating cash burn rate and quarterly cash position decline trajectory
- Revenue stabilization and any return to growth following 49.9% YoY decline
- Capital raise announcements, equity dilution, or strategic transaction necessity timeline
- Gross margin sustainability as company scales or pivots operations
- Cash and equivalents
- Operating cash flow (burn rate)
Longeveron Inc. (LGVN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Longeveron Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LGVN Profit Margin, ROE & Profitability Analysis
LGVN vs Healthcare Sector: How Longeveron Inc. Compares
How Longeveron Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Longeveron Inc. Stock Overvalued? LGVN Valuation Analysis 2026
Based on fundamental analysis, Longeveron Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Longeveron Inc. Balance Sheet: LGVN Debt, Cash & Liquidity
LGVN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Longeveron Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.62 indicates the company is currently unprofitable.
LGVN Revenue Growth, EPS Growth & YoY Performance
LGVN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $137.0K | -$4.4M | $-0.34 |
| Q2 2025 | $316.0K | -$3.4M | $-0.33 |
| Q1 2025 | $381.0K | -$4.1M | $-0.34 |
| Q3 2024 | $150.0K | -$4.4M | $-0.34 |
| Q2 2024 | $217.0K | -$3.4M | $-1.83 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Longeveron Inc. Dividends, Buybacks & Capital Allocation
LGVN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Longeveron Inc. (CIK: 0001721484)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LGVN
What is the AI rating for LGVN?
Longeveron Inc. (LGVN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LGVN's key strengths?
Claude: Gross margin of 67% demonstrates acceptable unit economics if revenue scale could be achieved. Minimal debt burden with Debt/Equity of 0.03x reduces financial leverage risk. ChatGPT: Low financial leverage (Debt/Equity 0.03x). High gross margin on limited revenue (67%).
What are the risks of investing in LGVN?
Claude: Critical cash runway of approximately 3 months based on $4.7M cash against $18.6M annual operating burn rate. Revenue collapse of 49.9% YoY signals severe loss of commercial traction or clinical setbacks. ChatGPT: Severe cash burn with limited cash balance implying near-term financing/dilution risk. Extremely negative profitability (Operating margin -1942%, Net margin -1894%).
What is LGVN's revenue and growth?
Longeveron Inc. reported revenue of $1.2M.
Does LGVN pay dividends?
Longeveron Inc. does not currently pay dividends.
Where can I find LGVN SEC filings?
Official SEC filings for Longeveron Inc. (CIK: 0001721484) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LGVN's EPS?
Longeveron Inc. has a diluted EPS of $-1.29.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LGVN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Longeveron Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LGVN stock overvalued or undervalued?
Valuation metrics for LGVN: ROE of -400.1% (sector avg: 15%), net margin of -1,893.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LGVN stock in 2026?
Our dual AI analysis gives Longeveron Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LGVN's free cash flow?
Longeveron Inc.'s operating cash flow is $-18.6M, with capital expenditures of $245.0K. FCF margin is -1,575.5%.
How does LGVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,893.6% (avg: 12%), ROE -400.1% (avg: 15%), current ratio 1.33 (avg: 2).